These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
200 related items for PubMed ID: 22808954
1. Two centuries of assessing drug risks. Avorn J. N Engl J Med; 2012 Jul 19; 367(3):193-7. PubMed ID: 22808954 [No Abstract] [Full Text] [Related]
2. AIHP Kremers Award Address 2006. Pharmacovigilance and the missing denominator: the changing context of pharmaceutical risk mitigation. Daemmrich A. Pharm Hist; 2007 Jul 19; 49(2):61-75. PubMed ID: 18368740 [No Abstract] [Full Text] [Related]
3. The Federal Food and Drug Administration in the United States: born and bred in crises. Taylor WJ. Int J Clin Pharmacol; 1973 Apr 19; 7(2):156-62. PubMed ID: 4581340 [No Abstract] [Full Text] [Related]
4. Rofecoxib, Merck, and the FDA. Kim PS, Reicin AS. N Engl J Med; 2004 Dec 30; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625342 [No Abstract] [Full Text] [Related]
5. Rofecoxib, Merck, and the FDA. Wolfe MM. N Engl J Med; 2004 Dec 30; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749 [No Abstract] [Full Text] [Related]
6. The 1941 sulfathiazole disaster and the birth of good manufacturing practices. Swann JP. Pharm Hist; 1999 Dec 30; 41(1):16-25. PubMed ID: 11623769 [No Abstract] [Full Text] [Related]
7. Vioxx's history and the need for better procedures and better testing. Gilhooley M. Seton Hall Law Rev; 2007 Dec 30; 37(4):941-68. PubMed ID: 18363218 [No Abstract] [Full Text] [Related]
8. Rofecoxib, Merck, and the FDA. Villalba L, Witter J. N Engl J Med; 2004 Dec 30; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745 [No Abstract] [Full Text] [Related]
9. What is a 'safe' drug? Healy B. US News World Rep; 2004 Dec 13; 137(21):37. PubMed ID: 15636504 [No Abstract] [Full Text] [Related]
10. Failing the public health--rofecoxib, Merck, and the FDA. Topol EJ. N Engl J Med; 2004 Oct 21; 351(17):1707-9. PubMed ID: 15470193 [No Abstract] [Full Text] [Related]
11. Frances Oldham Kelsey. FDA medical reviewer leaves her mark on history. Bren L. FDA Consum; 2001 Oct 21; 35(2):24-9. PubMed ID: 11444245 [No Abstract] [Full Text] [Related]
12. Bioequivalence: the regulatory career of a pharmaceutical concept. Carpenter D, Tobbell DA. Bull Hist Med; 2011 Oct 21; 85(1):93-131. PubMed ID: 21551918 [Abstract] [Full Text] [Related]
14. Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act. Wax PM. Ann Intern Med; 1995 Mar 15; 122(6):456-61. PubMed ID: 7856995 [Abstract] [Full Text] [Related]
15. Drug safety special: chasing shadows. Frantz S. Nature; 2005 Mar 31; 434(7033):557-8. PubMed ID: 15800592 [No Abstract] [Full Text] [Related]
16. Allied against reform: pharmaceutical industry-academic physician relations in the United States, 1945-1970. Tobbell DA. Bull Hist Med; 2008 Mar 31; 82(4):878-912. PubMed ID: 19075387 [Abstract] [Full Text] [Related]
17. Experts call for active surveillance of drug safety. Wadman M. Nature; 2007 Mar 22; 446(7134):358-9. PubMed ID: 17377551 [No Abstract] [Full Text] [Related]
18. The Atlanta Falcon and Tono-Bungay: dietary supplements as subprime drugs. Weissmann G. FASEB J; 2009 May 22; 23(5):1279-82. PubMed ID: 19406845 [No Abstract] [Full Text] [Related]
19. Some therapeutic disasters and their repercussions. Wolff F. Med Ann Dist Columbia; 1967 Feb 22; 36(2):81-7. PubMed ID: 5341220 [No Abstract] [Full Text] [Related]
20. 150 years of pharmacovigilance. Routledge P. Lancet; 1998 Apr 18; 351(9110):1200-1. PubMed ID: 9643710 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]